Citius Pharmaceuticals, Inc.

Analysis for Ticker: CTXR

Citius Pharmaceuticals Inc develops specialty medicines for critically ill patients focusing on treatments for rare cancers and serious bloodstream infections. While it claims to be a medical company the internal math reveals a machine designed to transfer investor cash into the pockets of executives and outside laboratories through a series of debt traps. Since its inception in 2007 the company has never generated a profit instead accumulating a massive deficit of over 247$ million. This is a financial disaster because the company has already signed away the majority of its future potential earnings to larger pharmaceutical firms leaving regular shareholders to fund a business that primarily exists to pay its own managers and creditors. The timeline of this decay became clear as the company reported a loss of 40,1$ million in 2024 followed by another 37,4$ million loss in 2025. Despite these mounting losses the people running the show continued to take millions from the treasury. Chief Executive Officer Leonard Mazur saw his total pay grow from 3,5$ million in 2024 to 4,5$ million in 2025. Other top managers like Myron Holubiak and Dr Myron Czuczman each extracted roughly 2,5$ million in 2025. Five different board directors including Suren Dutia and Carol Webb were paid between 681.523$ and 730.213$ each during the same year the company made zero revenue.